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1. Introduction 
1.1 Single-use vs. multiple use medical devices 
During the 1960s and the early 1970s, most medical devices made of glass, rubber, or metal 
were generally considered to be reusable. This concept did not change until the late 1970s, 
when medical devices started to enter the market labelled “single-use only” . 
During the same decades, clinical medicine has undergone substantial changes, with 
traditional open surgical procedures giving way to new minimally invasive techniques such 
as endovascular and laparoscopic intervention. Such procedures required new instruments 
allowing delicate and complex manipulations through small incisions, with the effector 
portion of the device located some distance from the operator’s hand, demanding stable and 
predictable performance. During this same period, patients and clinicians have become 
increasingly concerned about the risk of infectious disease transmission, particularly human 
immunodeficiency virus and hepatitis B and C viruses. 
One solution to both demands was found in single-use devices (SUDs), shaped from newly 
developed fabrication materials, firstly polymers, and intended to be discarded after use on 
a given patient. Consequently, the past three decades have seen an explosion in the 
production and use of single-use medical devices, stemming from a desire to improve 
product performance and minimize the potential for disease transmission, and enabled by 
advances in manufacturing techniques. 
1.2 SUDs reprocessing  
Although a number of advantages are related to the use of disposable goods in medicine, 
single-use devices are typically more costly on a per-use basis. SUDs are relatively 
expensive to purchase and their one-patient/ one-product nature made necessary 
enlargement of hospital inventories and the resulting stream of medical waste.  
These aspects have led to the interest in reprocessing and reuse of these devices. Many 
hospitals began to explore the reprocessing and a limited reuse of products intended for 
single use, initially using on-site facilities as they have traditionally done with multiple-use 
metallic surgical instruments. As single-use products became more complex, hospitals 
began to turn to third-party reprocessors to handle reprocessing needs. 
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Differently from the simple re-sterilization, the reprocessing practice is generally perceived 
to mean the cleaning, disinfection and sterilization of a medical device, including related 
procedures, as well as the functional testing and repackaging, carried out on a medical 
device after it has been put into service (EU Public Consultation, 2007). 
Reprocessing and reuse of SUDs have gained wide popularity in the last years as a result of 
the escalating cost of health care. A survey conducted in 2000 revealed that approximately 
20%—30% of hospitals in the United States reprocess SUDs (GAO, 2000). Data are likely 
underestimated because hospitals tend not to report their use of reprocessed SUDs. 
According to the United States General Accounting Office, substantial cost savings can be 
achieved by reprocessing SUDs because the cost of in-house reprocessing can be less than 
10% of the cost of a new device and the cost of third-party reprocessing is approximately 
50% of the cost of a new device (GAO, 2000). A national survey in Canada, investigating the 
current practices of reprocessing and reusing SUDs in Canadian acute-care hospitals 
indicates that 28% of hospitals participating in the survey reprocessed single-use devices 
(Polisena et al., 2008), and gave an overview on the types of SUDs most frequently 
reprocessed at acute-care hospitals in Canada. 
The basic and legitimate questions before starting a reprocessing policy are: i) Are 
reprocessed SUDs as good as the original devices in terms of chemical and physical 
characteristics? ii) Is it safe and economically convenient to use reprocessed SUDs? iii) How 
should reprocessing be regulated to ensure public health? 
In a commentary on reusing SUDs it is agreed that the answer to these questions depend on 
to whom they are addressed (Quian & Castaneda, 2002). Most of the opposition against 
reprocessing of SUDs comes from the original equipment manufacturers (EUCOMED, 2002), 
whereas the medical community is generally supportive of reprocessing (Lindsay et al., 
2001). In general, legislation advocates the precautionary approach till scientific evidences 
are sufficient to guarantee safeness and efficiency. Anyhow, commentary in the scientific 
literature on this subject is relatively sparse.  
1.3 The current status about reprocessing SUDs 
Nowadays, the practice of reusing SUDs prevails in almost all developing countries of 
Africa, Asia, Eastern Europe, Central America, and South America, where there are 
shortages of medical supplies and financial resources (Quian & Castaneda, 2002). The 
rationale behind the reuse of disposable devices in these countries is simple and forceful. 
The overwhelming public demand for minimally invasive procedures made the single-use 
of devices financially and ethically unsustainable: otherwise, only those patients with 
sufficient resources would avail themselves of these new procedures because public 
institutions could not afford the use of disposable devices for the indigent population 
(Ruffy, 1995). 
The evidence for the safety and effectiveness of reusing SUDs is indirect with the majority of 
studies set in laboratory contexts evaluating surrogate outcomes such as medical device 
integrity and contamination after reprocessing. Few studies involved outcomes directly 
related to patients. It is difficult to define adequately a direct causal link between patient 
exposures to contaminated or faulty medical devices and adverse patient outcomes due to a 
lack of data on cross-infection and loss of device functionality. 
Conflicting results comes from the available studies. Some studies concluded that the reuse 
of SUDs is potentially safe and effective with strict reprocessing protocols and standards. 
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Others do not recommend reprocessing and reuse because the evaluated devices were not 
clean or sterile and changes in device integrity were evident. These conflicting results were 
apparent for anaesthesia devices (Daggan et al., 1999; Lipp et al., 2000), airways devices 
(Vezina et al., 2001), and disposable plastic trocars (Chan et al., 2000; Roth et al., 2002). The 
reprocessing and reuse of sphincterotome devices was considered safe and effective with 
proper reprocessing standards (Kozarek at al., 1999). Studies investigating biopsy forceps 
consistently showed that reprocessing standards were not met as the devices were not clean 
nor sterile (Hambric 2001, Kinney et al., 2002). In general, there are ethical constraints in 
using patients in studies designed to determine the ‘risk’ associated with reusing SUDs, 
thereby limiting the overall evidence base. However, despite the existence of some 
recommendations and protocols governing the reuse of SUDs many items are still being 
reprocessed and reused without definitive evidences on the safety of these practices. 
Reports of cases where the use of reprocessed medical devices intended for single-use have 
caused harm to patients are scarce. It is thus difficult to estimate the incidents frequency as, 
in general, the personnel involved is likely to be reluctant to report the incidents for 
insurance or other reasons. In most European countries, the reporting of incidents is not 
mandatory. In the United States, reporting of incidents involving medical devices is 
mandatory and all reported incidents are integrated into a searchable database. However, 
when analysing the reported incidents, the Government Accounting Office did not find any 
evidence that reprocessed SUDs caused more incidents than other devices (GAO, 2008). 
2. Reusing SUDs in interventional cardiology 
Nowadays, one of the few areas where reprocessing and reuse of SUDs seems suitable both 
for safeness and cost effectiveness is interventional cardiology (Lindsay et al., 2001; 
Bourassa, 1996, CETSQ, 1994; Krause et al., 2000; Day, 2004). Radiofrequency catheter 
ablation and percutaneous transluminal coronary angioplasty have emerged as important 
therapeutic options for patients suffering respectively from a variety of arrhythmias and 
coronary diseases. A significant portion of the cost for the procedure is represented by the 
cost of the multielectrode diagnostic and ablation electrophysiology catheters (EP) or the 
coronary angioplasty balloon catheter (PTCA). Both catheter types are nowadays labelled 
and marketed as single use only.  
Similarly to other SUDs, in the past, as the demand for disposable equipment rose, hospital 
administrators and physicians began to notice that some products labelled “single use only”  
were similar to devices that had been formerly distributed as “reusable” . It was reported 
about a letter by one of the major cardiac catheter manufacturer that stated, “our 
manufacturing processes of Woven Dacron Intracardiac Electrodes have not changed. These 
electrodes are made with the same materials and in the same manner they have been in the 
past”  (CCHR, 2000). In response to what many physicians and hospital administrators 
perceived as an arbitrary labelling policy, the practice of reprocessing SUDs evolved to 
reduce costs and the amount of medical waste. As this practice encompassed critical devices 
such as electrophysiology and PTCA catheters the complexity of decontamination and 
sterilization procedure increased. The role of hospital committees (physicians, nurses, 
infection control specialists, risk managers, hospital lawyers, and professional reprocessors) 
evolved to monitor the safety of repeocessing methods. Many hospital administration 
believed this practice was safe, some made use of third party reprocessors, and others 
abandoned the practice altogether. 
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In the present context, material and technological advancements brought to produce and 
place on the market high-quality and technologically advanced devices for interventional 
cardiology with higher therapeutic efficiency but considerably more expensive 
interventions. Considering the worldwide shortening of economic resources in healthcare 
systems, the issue of reuse and reprocessing feasibility in a field like interventional 
cardiology, reveal a great interest and represent a very topical problem. 
2.1 The clinical knowledge on reprocessing SUDs in interventional cardiology 
The issue of reprocessing single use devices in interventional cardiology has been debated 
from many years and literature presents some investigations which have been conducted to 
explore technical feasibility, safety, and efficacy of introducing a reprocessing policy in 
hospital and health care institutions (Bloom et al., 1997; Blomstrom-Lundqvist, 1998; 
Azyman et al., 2002; Brown et al., 2001; Browne et al., 1997; Chaufour et al., 1999; Granados 
et al., 2001; Luijt et al., 2001; Ma et al., 2003). Available scientific evidences are of utmost 
importance for in deep addressing this topic and pointed out the need for new experimental 
data on technical feasibility, and clinical effectiveness since new materials, manufacturing 
advancements and substantial technological improvements are frequently introduced in the 
production of new medical device generations.  
Some clinical studies tried to convey clinical data on safety and efficiency by introducing 
reprocessing and reuse practices in the interventional context and retrospectively or 
prospectively evaluating patients’ outcome. Moreover, some case studies highlighted 
important benefits and limitations of the reprocessed instrumentation that arose during 
clinical reuse. All these evidences will constitute the starting point for approaching the 
reprocessing issue and formulating recommendations and guidelines even more efficient 
and precise. 
The issues pertaining to the safety and efficacy of reusing catheters focus on the risk of 
transmitting an infection from one patient to an other and the structural and functional 
integrity of a catheter that is used more than once on different patients. Differently from 
resterilization procedures that are quite well established, protocols for SUDs disinfection 
and cleaning are often lacking or improperly designed. Moreover, objective procedure for 
the measurement of catheter integrity and functionality are not as well documented since 
they are highly related to materials and design. Some catheters are subjected to very little 
stress during a procedure, while the deflectability or manoeuvrability of others may change 
considerably. Lumen cleaning, disinfection and patency are critical due to the peculiarity of 
catheter design and, sometimes, rapid and effective procedures are to be implemented. 
Moreover, reprocessing may affect catheter materials and could have a significant impact on 
functionality. 
2.2 Electrophysiology and ablation (EP) catheters 
A few published studies have evaluated the safety of reusing catheters for 
electrophysiological studies and have addressed some of these issues. O’Donoghue and 
Platia surveyed 12 medical centres to determine the safety of reusing EP catheters 
(O’Donogue & Platia, 1988). The incidence of infection related to a total of 14640 
electrophysiological studies, involving 48075 catheter uses, was reported. At three centres, 
catheters were automatically discarded after a single use. These centres carried out 1245 
electrophysiological studies using 3125 catheters. At the other nine centres, the catheters 
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were sterilized for reuse. There were 13395 interventions using 44950 catheters in the reuse 
group. The incidence of bacteraemia (blood borne infection) and superficial skin infection at 
the site of catheter insertion were respectively 0.03% and 0.03% for the single use group and 
0.018% and 0.002% for the reuse group. The authors concluded that sterilization and reuse 
of the catheters used in this study did not result in an increase in the risk of infection. They 
felt the catheters were sufficiently durable to be reused well in excess of five times, and that 
one-time use of such catheters appeared to be an unnecessary and expensive policy. 
Dunnigan et al. obtained similar results in a prospective study that evaluated catheter reuse 
over a 5-year period during which 178 catheters were used 1576 times for 847 
electrophysiological studies (Dunnigan et al., 1987). No complications were encountered 
during the study period. All reused catheters were effective for cardiac pacing and 
recording of cardiac electrical signals. Surveillance cultures and biological indicators 
revealed that adequate steri1ization procedures were used. The authors concluded that 
electrophysiological catheter may be safely reused provided a thorough cleaning, testing, 
and record keeping system is instituted. They also concluded that the practice of reusing 
catheters would result in substantial cost savings to hospitals. 
The clinical trials presented above were conducted in patients undergoing diagnostic 
electrophysiological studies before the advent of deflectable catheters and arrhythmia 
ablation procedures.  
Avital et al. prospectively investigated the time course of electrical, physical, and 
mechanical changes in ablation catheters to determine the effect of reuse on safety and 
efficacy (Avital et al., 1993). They studied 69 ablation catheters made by a single 
manufacturer that were used in 336 procedures. Testing of physical integrity consisted of 
visual and stereoscopic examination of handle function, catheter shaft, and the deflectable 
tip. Specific attention was paid to the ablation electrode attachment to the catheter shaft, and 
the ablation tip electrode was scrutinized for pitting. The electrical integrity of the catheters 
was checked by measuring the electrical resistance from the handle connector to the 
recording rings and to the tip electrode. Deflection and torque measurements were made to 
assess mechanical integrity. During the course of this study, 36 catheters (52%) were rejected 
at some point because of mechanical or electrical failure. Eighteen catheters were repeatedly 
sterilized and 11 of the catheters were used 10 times. The most common reasons for catheter 
rejection were tip electrode glue separation after 4.3±4.3 uses and loss of deflection after 5.0 
± 3.3 uses. The glue that covers the most proximal portion of the distal electrode was shiny 
and uniform before any use. The application of radiofrequency energy causes a rise in tissue 
temperature and the electrode tip is heated secondarily. Small fractions of glue were missing 
and may have been released into the bloodstream. Catheters with blood that collected in this 
space could not be properly cleaned. There was no evidence that the tip to shaft attachment 
was affected by the outer glue separation; however, the possibility that the attachment of the 
tip electrode was weakened by the glue separation was not excluded by the authors. 
Electrical discontinuity was observed after 10.0±3.7 uses. There was no significant decrease 
in the catheter torquing ability that determines the steering responsiveness of the catheter. 
The medical records of 140 patients who had arrhythmia ablation procedures in this study 
revealed only one case (0.7%) of local infection at the insertion site that was treated 
effectively by antibiotics. There were no other complications. 
Avital and co-workers concluded that the catheter model used in this study could be reused an 
average of five times. They recommended that, after each use, catheters be carefully examined 
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under magnification with special attention to the tip electrode. They also recommended that 
the catheters be tested for deflection and electrical integrity after each use. 
As part of an internal quality review process Aton et al. determined the effects of 
reprocessing on mechanical integrity, sterility, and chemical residuals to establish and 
validate an institutional policy for reuse (Aton et al., 1994). A total of 12 commercially 
available catheters from two manufacturers were analysed. Eleven of the catheters were 
randomly selected from the catheter inventory of the clinical electrophysiological laboratory 
after being used one to four times. They were manually cleaned, repackaged, and gas 
sterilized with ethylene oxide. To assess the sterility of reused catheters, three were cut into 
2-inch segments, placed in bacterial culture media, and incubated for 5 days. Six of the 
catheters were analysed for chemical residuals after gas sterilization. Two catheters were 
examined for evidence of component failure. Visual inspection and microscopy were used to 
determine the mechanical integrity of the catheter surface, and x-ray inspection was 
performed to assess interior structures. 
The study results of Aton et al. showed no bacterial growth detected on any of the cultures, 
which indicated that reprocessed electrode catheters are effectively sterilized. The chemical 
analysis demonstrated that the concentrations of ethylene oxide detected in extraction liquid 
exceeded standards established by the FDA. Microscopic examination of reprocessed 
catheters demonstrated inconsequential metal and fibre particulates on the catheter surface 
and at some electrode to catheter interfaces. Fluid entrapment around the distal pole may 
occur in catheters with tip electrodes. The shaft of the catheters and the electrodes remained 
intact. No evidence of electrical discontinuity was found and the integrity of the internal 
structures was confirmed by x-ray inspection. The authors concluded that, with the 
sterilization techniques frequently used at that time by hospitals, the potential for chemical 
residual contamination might exist after sterilization with ethylene oxide. 
2.3 Percutaneous coronary angioplasty (PTCA) catheters 
Similarly to EP catheters, a few clinical trials were performed to assess safety and efficiency 
of PTCA reprocessed catheters and only a single randomised, double blind, clinical trial was 
found in the English literature. 
In 1994 a first relevant and debated study by Plante et al. was designed to determine the 
effectiveness, safety and costs associated with reuse of angioplasty catheters and to compare 
these results with those of a contemporary centre that employed a single-use strategy in 
Canada (Plante et al., 1994). In a prospective observational study, data forms were 
completed after each angioplasty procedure and before patient discharge over a 10-month 
period. A total of 693 patients were enrolled in the two centres. Clinical and lesion 
characteristics were similar except for a higher incidence of unstable angina at the reuse 
centre. The angiographic success rate was identical (88%) at both centres, but the reuse 
strategy was associated with a higher rate of adverse events, prolonged procedure time and 
increased use of contrast medium, especially in lesions that were not crossed by the initial 
balloon and in patients with unstable angina. Whether these differences are related to the 
reuse strategy or to differences in patient groups cannot be ascertained by this observational 
study as pointed out by Rozeman and colleagues (Rozemann et al., 1995). 
Mak et al. re-evaluated clinical data from Plante’s study using a multivariate statistical 
model with the purpose to control for the differences in the baseline clinical characteristics 
of the patients at the two centres and to determine if catheters reuse was associated with an 
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increase in complication rate (Mak et al., 1996). The reanalysis showed that the reuse of 
balloon catheters was not associated with an increased in-hospital event.  
A study conducted in the United States by Browne and co-workers aimed at evaluating the 
performance of angioplasty catheters, restored under a strict remanufacturing process 
(Browne et al., 1997). Used PTCA balloon catheters were shipped to a central facility and 
were decontaminated, cleaned and tested for endotoxins. Physical testing and quality 
assurance were performed before the products were packaged and sterilized with ethylene 
oxide. Catheter performance was assessed in a pilot study powered to detect a 5% difference 
in the angiographic failure rates of new and reused balloons. Under specific indication for 
PTCA procedure, 107 patients were enrolled, 106 had a successful laboratory outcome, and 1 
required coronary artery bypass graft surgery after failed rescue stenting. Over 122 lesions 
attempted, the angiographic failure rate was 7% (10 of 108) comparable to the 10% rate seen 
with new balloons in other studies. Authors concluded that restoration of disposable 
coronary angioplasty catheters using a highly controlled process appears to be safe and 
effective, with success rates similar to those of new products and no detectable loss of 
performance. Moreover the reported cost analysis suggested that implementation of reuse 
technology for expensive disposable equipment may offer cost savings for U.S. hospitals, 
without sacrifice of quality. 
Shaw et al. examined the effects of catheter reuse on duration of PTCA procedures and 
clinical outcomes by retrospectively analysing clinical data of two patients group isolated 
before and after July 1996 in Canada (Shaw et al., 1999). In July 1996, because of concern 
regarding the possible transmission of Creutzfeldt-Jakob disease, the province of Quebec 
stopped the reuse of PTCA catheters. Prior to this time, PTCA balloon catheters were 
commonly used a maximum of four times in the enrolled health centre. After this time, only 
new catheters were used. Fifty-three consecutive patients undergoing PTCA prior to 21 July 
1996 were compared with 54 consecutive patients undergoing PTCA after that time. It was 
concluded that there were no significant differences between the single-use and reuse 
groups with respect to baseline characteristics, no significant differences in the numbers of 
PTCA catheters used (97 vs. 103) or angiographic success rates (88% vs. 83%). Authors 
stated that, if catheter reuse is not found to be associated with infectious disease 
transmission, its widespread use should be considered. 
The first randomised, double-blind, controlled, single centre, clinical trial has been 
performed by Zubaid and colleagues (Zubaid et al., 2001).  The study compared the safety 
(clinical success) and efficacy (angiographic success) of reused versus new coronary 
angioplasty balloon catheters on a total of 377 procedures, 178 performed by reused 
catheters and 199 by new catheters. No significant differences in clinical or lesion 
characteristics between the two approaches were found. The incidence of first balloon 
failure in reused catheter was similar to that of the new catheter (7% vs. 5%) and the 
angiographic success rate was also similar with 176 cases (98.9%) in reused catheters and 
196 cases (98.5%) in new catheters. The number of balloon catheters used per lesion, amount 
of contrast, and procedural and fluoroscopy time were similar in the two arms. At 30 days, 
the incidence of major adverse cardiac events was similar in both cases (4.5% vs. 5%). The 
study concluded that, in a wide variety of patients, the clinical results of reused balloon 
catheters are similar to those of new catheters and reused catheters are as effective and safe 
as new catheters. 
A prospective randomised trial comparing new and reprocessed balloons, including stented 
and stand-alone balloons, has been more recently proposed by Unverdorben and colleagues 
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(Unverdorben et al., 2005). Percutaneous coronary interventions were performed randomly 
in 238 consecutive patients with either new or 1 to 3 times reused balloon catheters. 
Crossing of the stenosis decreased from 96% with new balloon catheters to 93.2%, with 1 
time reused balloon catheters to 81.8% with 2 times reused catheters and to 80.8%with 3 
times reused catheters. In all primary failures using resterilized balloon catheters, new ones 
of the same nominal diameter were successful. The angiographic follow-up rates were 77.4 
% for new balloon catheter, 79.5% for 1 time reused balloon catheters, 75.0 % for 2 times 
reused balloon catheters, and 80.8% for 3 times reused balloon catheters. The percent 
stenosis was higher in reused versus new balloon catheters, as was the restenosis rate. There 
was one death in reused balloon catheter category but no event of myocardial infarction. 
Rates of target lesion revascularizations were similar in stent recipients and more frequent 
after stand-alone balloon angioplasty with reused versus new balloon catheters. According 
to clinical data, authors concluded that the use of two or three times resterilized balloon 
catheters does not seem to be justified in stand-alone balloon angioplasty of de novo coronary 
stenoses and should be limited to stent procedures until data will be available for other 
indications. 
2.4 Limitations of available clinical data 
Some criticisms could be made of the above reported studies. Retrospective surveys might 
depend on the memory of those who responded. Isolated events could escape the attention 
of the participants in the survey or they may have forgotten complicating events. Some of 
the prospective studies involved small numbers of patients. In general the methodology of 
these studies varied and is unlikely to meet recognized standards. Specifically, reprocessing 
procedures are not harmonized and sometimes not clearly reported. It is also unclear if the 
protocols used to reprocess the devices were insufficient or if the devices could indeed not 
be properly reprocessed. Studies claiming safety of reprocessed device do not cover any 
form of long-term observation of patients regarding the development of infectious diseases 
and/ or immunological complications following exposure. Moreover, the catheters used in 
the majority of these studies are old designs. Because changes in materials or/ and functions 
might have a significant impact on the durability of electrophysiology and angioplasty 
catheters, it should not be assumed that prior safety data is applicable to new catheter 
designs that are nowadays used in the clinical practice.  
This chapter aims at eliciting, discussing and integrating recent experimental findings for 
the assessment of a reprocessing policy on interventional cardiac catheters labelled as 
“single use only” . The experimental techniques here reviewed supply new parameters for 
the assessment of quality and safety of reprocessed devices before starting a clinical trial on 
patients. To this end, technical data and legal, ethical, and economic issues are integrated in 
order to define the applicability and suitability of SUDs reprocessing. 
3. Technical issues 
3.1 Chemical and physical analysis of new and reprocessed devices  
The reprocessing protocol should be conceived and designed according to the peculiar 
characteristics of the device to reuse (Fig. 1). Manufacturers of reusable devices are required 
to specify in details the proper cleaning, disinfection and (whenever required) sterilization 
methodologies for guaranteeing a safe and effective reuse on patient. Differently, disposable 
devices, labelled as “single-use only”  do not provide any information addressing for 
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reprocessing procedures. Moreover there is a diffused scarcity of materials and designs 
details on the accompanying documentation.  This lack of technical data demands for a 
complete and exhaustive characterization of the device, posing a particular attention to 
materials, coatings, and design.  
Tessarolo et al. applied a wide number of experimental analytical technique to address 
essential information about polymer composition and fillers, metals and coatings, surface 
and bulk parameters, mechanical and thermodynamic materials properties, micro and 
macro design of PTCA and EP catheters. The preliminary characterization of device, 
allowed to define detergents, procedures, and sterilization methods according to procedural 
standards, materials composition, and design. Long and narrow lumens of PTCA catheters 
demanded for ethylene oxide sterilization, while gas-plasma sterilization was applicable for 
non irrigated EP catheters (Tessarolo et al., 2004a). 
The reprocessing feasibility from a technical point of view has been evaluated on non-
irrigated electrophysiology and non-stented coronary angioplasty devices produced by the 
major worldwide manufacturers. Chemical-physical properties have been assessed on both 
new and reprocessed devices by using advanced analytical techniques for surface and bulk 
material characterization such as optical microscopy (OM), electron microscopy (EM),  
atomic force microscopy (AFM), and infrared spectroscopy (IR).  
 
 
Fig. 1. Representative electrophysiology (upper left) and angioplasty (upper right) catheter 
for interventional cardiology marketed as single-use only. Images in the bottom show distal 
portions of the catheters including the functional units: electrodes for recording endocardiac 
ECG signal and ablation of myocardial tissue (lower left) and an inflated ballon for coronary 
reprocessing, chemical and physical characterization was carried out at different number of 
arthery dilation in case of stenosis (lower right). The grid is 1x1mm squared. Adapted from 
Tessarolo et al., 2004a. 
To identify device alterations induced by clinical use and/ or reprocessing cycles catheters 
were characterized after clinical use,  simulated reuse, and repeated reprocessing (from 0 to 
14 cycles for EP and from 0 to 6 cycles for PTCA)  (Fedel et al., 2006; Tessarolo et al., 2004b; 
Tessarolo et al., 2005; Tessarolo et al., 2006a). OM on EP catheters revealed reprocessing-
dependent scratches on the polyurethane shaft’s surface (Fig. 2) (Tessarolo et al., 2004b). EM 
and AFM documented a physical-chemical etching on polymers, due to plasma sterilization, 
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and a significant increasing in nano-roughness after 7±4 cycles of reprocessing (Fig.3) 
(Tessarolo et al., 2004b).  
Residuals of iodate contrast medium in PTCA underlined the need for a timely and efficient 
cleaning of balloon lumen to avoid crystallization and loss of functionality. Infra-red 
spectrum suggests that ethylene oxide did not significantly modify polymer’s bulk 
characteristics (Fedel et al., 2006). These studies elicited that materials are highly model 
dependent and should be verified after each reprocessing cycles. Critical steps for materials 
modifications were identified in cleaning and sterilization phases. 
 
 
Fig. 2. Optical microscopy on EP catheter shafts. Scratches and indentations were caused by 
both clinical use and mechanical and/ or manual brushing during cleaning procedures. The 
amount of scratches was related to the number of reprocessing cycles. From left to right and 
from top to bottom: new device, 1, 4, 8 times regenerated devices. Bar is 20 µm. 
3.2 Functional testing of reprocessed devices 
To estimate the maximum number of reuses sustainable by the device in an effective status, 
functionality was assessed by realizing specific experimental set-ups for both EP and PTCA 
catheters. Tissue- and organ-synthetic phantoms were realized for simulating clinical use 
and obtaining quantitative an reproducible functional measurements. Radiofrequency 
ablation efficiency, electrical characteristics, and catheter slipperiness were quantified in EP 
devices until 10 cycles of reprocessing (Tessarolo et al., 2004a). Compliance curve, crossing 
profile, burst pressure, and slipperiness were checked at different steps of the protocol on 
new and reprocessed PTCA catheters up to three uses (Fedel et al., 2006). 
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Fig. 3. AFM on EP catheter shaft. Polyurethane underwent progressive nanometric 
roughening with repetitive gas plasma sterilization. Alterations were induced by the 
chemical and physical etching of the sterilization technique. From left to right and form top 
to bottom: new device, 1, 4, 8 cycles regenerated devices. Adapted from Tessarolo et al., 
2004b. 
Functionality tests on EP catheters elicited no variations in ablation efficiency, electrodes 
conductivity, thermometric sensor’s precision and accuracy (Tessarolo et al., 2005). 
Differently, slipperiness tests showed a worsening of lubricious properties in regenerated 
EP devices after 4 cycles in accordance to the increase of surface roughness. Conversely, 
functional properties of PTCA catheters were affected by both clinical use and 
reprocessing procedures (Fig. 4) (Fedel et al., 2006). As a consequence of the mechanical 
stress in clinical use, balloon diameter at nominal pressure tended to increase. Differently 
thermo-chemical stress due to cleaning and sterilization induced balloon shrinkage after 
the first reprocessing cycle. Subsequent cleaning and sterilization did not induce further 
dimensional alterations. However these modifications did not affect the performance of 
the device because compliance tests showed the conformity of reprocessed balloons 
within the 10% limit of acceptance of manufacturers’ original specifications. Anyway, the 
authors suggested that in case of PTCA catheter reprocessing, it would be profitable to 
introduce a new calibration curve, with new nominal diameter values. Slipperiness and 
friction patterns were strictly dependent on PTCA device manufacturer and model but the 
magnitude of modifications did not compromise in-vitro catheters functionality up to 
three uses (Fedel et al., 2006). 
www.intechopen.com




Fig. 4. Effects of cleaning and reprocessing on balloon working diameter (D) normalized to 
nominal specifications (ND). Data refer to new PTCA devices (full squares), and to products 
used once on patients (empty squares). The gap between new and used catheters could be 
caused by exceeding the nominal pressure during in vivo inflation. Both new and used 
catheters underwent a progressive shrinking after cleaning and first complete reprocessing. 
Adapted from Fedel et al., 2006.  
4. Hygienic issues 
Hygienic issue should consider a wide spectrum of microbiological tests at different steps of 
the reprocessing procedure. The bioburden after clinical use and decontamination should be 
quantified and decontamination-cleaning efficacy, pyrogenic load and device sterility have 
to be guaranteed. Pathogenic agents/ substances include: bacteria in vegetative or 
sporulated form, fungi, viruses, microscopic parasites, and prions which are agents 
responsible for transmissible spongiform encephalopathies. Furthermore, endotoxins (which 
are part of the bacterial cell wall of Gram-negative bacteria and can be responsible for septic 
shock) may remain on a SUD even after sterilization as they have a very high resistance to 
disinfection or sterilization processes. A specific hazard is the possible contamination with 
agents causing transmissible spongiform encephalopathies  as they are particularly resistant 
to commonly used physical and chemical methods of cleaning, disinfection and/ or 
sterilization. The causative agent of these diseases consists of the pathogenic isoform of the 
prion protein, which is misfolded into an infectious agent. It is known that iatrogenic 
infection of Creutzfeldt-Jakob disease can occur in specific situations associated with 
medical interventions (Armitage et al. 2009). To date, processes ensuring a total inactivation 
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of the transmissible spongiform encephalopathy agents are relatively aggressive precluding 
their application to materials used for the production of single-use medical devices (Fichet et 
al., 2004). Anyway, new association of chemical disinfection and low temperature gas 
plasma sterilization seemed are promising for prion inactivation from thermo-sensitive 
materials (Rogez-Kreutz et al., 2009). 
4.1 Collection, cleaning and disinfection of used devices 
Tessarolo et al. conducted cultural tests on patient-used catheters to determine and quantify 
the possible microbial species which could contaminate devices surfaces in clinical 
procedures (Tessarolo et al., 2004a). Cultural quantitative test on PTCA devices showed that 
50% of the samples were contaminated after use with a microbial bioburden lower than 6 
CFU per device (Table 1). Isolated genera were typical of the skin resident microbial flora. 
Equivalent test on clinically used catheters subjected to decontamination confirmed that 
inappropriate or untimely procedures might generate bacterial contamination and microbial 
dissemination in formerly sterile device’s surfaces (Table 2). Moreover the use of low quality 





Isolated species Notes 









C 2 CFU Staphylococcus aureus - 




E 4 CFU 
Staphylococcus spp. 
Corynebacterium spp. 
Positive culture of the distal tip 
Corynebacterium jeikeium 
F 1 UFC 
Staphylococcus. 
auricolaris 
Positive culture of the lumen 
eluate 
G sterile - - 
H sterile - - 
I sterile - - 
L sterile - - 
M sterile - - 
N sterile - - 
Mean 
device 
2 CFU   
Table 1. Bioburden on PTCA catheters immediately after use on patients. In 50% of the 
examined catheters showed the growth of typical resident microbial flora of the skin. A very 
low number of CFU per devices was revealed as outlined in the “mean devices”  bacterial 
load. 
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Isolated species Notes 




P 109 CFU 
Staphylococcus spp. 
 
Distal tip: S. warneri 
Lumen eluate: S. auricolaris 












S sterile - - 
Mean 
device 
25 CFU   
Table 2. Bioburden on PTCA catheters used on patients and decontaminated. A significantly 
higher number of CFU per device was revealed in respect to used but untreated devices (See 
Table 1). CoNS: Coagulase negative staphylococci  
 
 
Fig. 5. Scanning Electron Microscopy on decontaminated and cleaned EP catheter by four 
different protocol: 1) chlorine-enzymatic solutions 2) enzymatic-chlorine solutions; 3) 
polyphenolic emulsion 4) polyphenolic plus enzymatic treatment. From top to bottom and 
from left to right is reported the electrode-shaft interface of catheter after protocol 1, 2, 3, 
and 4. Adapted from Tessarolo et al., 2004c and Tessarolo et al., 2007a. 
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Fig. 6. Survival of P. aeruginosa after the exposure of the contaminated catheter shaft to the 
same four different protocol for decontamination and cleaning described in Fig 5. Colony 
count was performed at 24 and 48 hours to evidence any eventual bacteriostatic effect. Initial 
bacterial load (conrol) was 1.6x105 CFU per catheter.  
 
 
Fig. 7. Electron microscoscopy images of biologic residuals including Bacillus subtilis in 
catheters processed for resterilization. Left: Low-vacuum SEM at electrode-polymer 
interface showing bacterial shaped corpuscles embedded in the organic coating residual. 
Sporulated (black arrowheads) and vegetative (white arrowheads) forms of B. subtilis might 
be associated to this debris according to morphology and size. Right: TEM on a ultrathin 
section (bar is 1µm) of blood clot scraped from the catheter surface after treatment by 
polyphenolic solution and enzymatic detergent. The inclusion of B. subtilis in vegetative 
and sporulated forms are shown. TEM image was negative filtered. Adapted from Tessarolo 
et al.  2007a. 
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Since the efficacy of pre-sterilization device treatments is fundamental for sterilization 
success, different decontamination, disinfection and cleaning protocols were tested to 
identify biocide properties and cleaning effectiveness. Tessarolo and co-workers reported 
about 80 catheters samples, contaminated with bacteria-spiked human blood and subjected 
to different pre-sterilization protocols including chlorine releasing agent, polyphenolic 
emulsion, and enzymatic detergent (Tessarolo et al., 2004c; Tessarolo et al., 2007a). Treated 
samples were analysed by electron microscopy for biologic and inorganic residuals 
characterization, while cultural quantitative methods assessed chemicals’ bactericidal 
effectiveness. Significant differences by using different chemicals were found. The use of 
chlorine solution as first treatment left relevant blood residuals on the exposed device 
surfaces while protocols including the polyphenolic emulsion, realized a deep cleaning of 
the surfaces with a very limited lasting bioburden (Fig. 5). Interaction and absorption of 
polyphenols on polymers has to be also considered for potential toxicity in re-use. Cultural 
quantitative methods showed the highest biocide properties of hypochlorous-acid based 
protocols while a lower bactericidal activity was documented for polyphenolic based 
solutions (Fig 6). Authors elicited the need to optimize both the disinfection efficiency and 
the biologic burden removal. It is also mandatory to provide for protecting the personnel 
from infectious agents. This threefold aim ask for defining structured protocols based on the 
synergic integration of mechanical and chemical agents. 
Finally, the problem of pyrogenic risk related to reuse of single use devices, got in contact 
with blood, was specifically addressed (Tessarolo et al., 2006b). With this purpose the 
pyrogenic status of 61 catheters was monitored in three fundamental steps of the 
reprocessing protocol: untreated, after decontamination-cleaning procedure and after 
complete reprocessing. Endotoxin content was assayed by LAL test both after standard 
clinical use conditions and worst-case contamination by in-vitro high inocula endotoxins 
spiking. Experimental results demonstrated that standard clinical use did not represent a 
critical source of endotoxins contamination. Differently, the use of tap water and manual 
cleaning processing increased the pyrogenic load by introducing gram-negative 
microorganisms and by favouring bacterial growth on residual moisture. Microbiologically 
high quality water for limiting gram-negative contamination and overgrowth, is mandatory 
to avoid pyrogenic risk in reusing single use devices. Microbiological data suggested that 
the use of automated cleaning system instead of or in addition to manual device processing 
is more suitable for guaranteeing a reliable and standardized cleaning of complicated 
designs and sensitive materials. 
4.2 Sterilization of processed SUDs 
High-sensitive and reproducible sterility testing methodologies were developed by 
Tessarolo and co-workers to evaluate performances and limitations of a regeneration 
protocol for EP catheters (Tessarolo et al., 2006c). Devices were collected after clinical use on 
patient, underwent repeated cycles of simulated-use (bacteria spiked blood) and 
regeneration (decontamination, cleaning and sterilization), and were cultured for 28 days in 
trypticase soy broth. Sterility tests provided experimental evidences on 208 samples, six 
cycles of regeneration, and four inoculating bacteria species. Sterility investigations showed 
no positive sample to the inoculated strain until the fourth cycle of reprocessing (Table 3). 
The inoculated Bacillus subtilis strain was recovered in samples reprocessed five and six 
times. These results were in accordance with surface analysis which pointed out alterations 
on materials’ properties that might favour bacterial persistence and limit reprocessing 
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effectiveness after repeated reprocessing cycles. Hence, over-reuse of the devices could 
affect both safeness and efficacy as documented by sterility data and surface worsening after 
five reuses (Tessarolo et al., 2004b, Tessarolo et al., 2006c). Coming from experimental 
conditions conducted in worst case scenarios, this estimation of the maximum number of  






to inoculated strain 
Positive devices 
to inoculated strain % 
I regeneration 54 N.A. N.A. 
II regeneration 36 0 0% 
III regeneration 24 0 0% 
IV regeneration 28 0 0% 
V regeneration 35 1 2.9% 
VI regeneration 22 1 4.5% 
Table 3. Sterility tests on EP catheters. Regeneration procedures were ineffective in restoring 
sterility of devices reused more than five times. Data are reported for 2nd to 6th 
regeneration after simulated in-vitro contamination by using bacterial spiked human blood 
(107 CFU/ mL.). Due to first patient clinical use, data on possible contaminating species in I 
regeneration lot are not available (N.A.). Adapted from Tessarolo et al., 2006c. 
5. The ethical and legal context 
5.1 Juridical issues about reprocessing SUDs 
There is no uniform policy governing the reuse of SUDs in the European Community. 
Finland, France, Germany, UK, Portugal, Spain and Sweden have all introduced various 
degrees of regulation (including a total ban) on refurbishing and reuse of SUDs. Despite 
this, the practice remains present in EU countries.  
Directive 93/ 42/ EEC on medical devices (MDD), adopted on 14 June 1993, stated that 
medical devices intended for single-use must bear on their label an indication that the 
device is for single-use. Directive 2007/ 47/ EC, adopted on 5 September 2007, amending 
Directive 93/ 42/ EEC, provided further clarification defining a “single-use”  medical device 
as “a device intended to be used once only for a single patient” . The Directive also 
introduced the requirement that if the device is for single-use, information on characteristics 
and technical factors known to the manufacturer that could pose a risk if the device were to 
be re-used must be provided in the instructions for use. According to the Directive and to 
national legislations of European countries, producers of medical devices are held to 
guarantee the number of times the product can be reused, assuming the complete liability 
during the whole life cycle. A disposable device ends its intended life after the first use so 
losing any manufacturer’s responsibility for subsequent reuse. On the other hand, in most of 
European countries, no bans are clearly provided by the law for a reprocessor who intends 
to enter in the market proving a safe reuse of this kind of devices. The freedom of enterprise 
and the free competition, submitted to strict market regulation, could in fact promote 
competition and products improvement. Consequently, many European countries assumed 
that the certificate of conformity system should be extended to the reprocessor’s activity, 
since CE mark is a guarantee for product compliance with all of the essential requirements 
for medical devices. 
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In the United Kingdom, France, Spain, and Switzerland, recommendations, legislation, or 
notes have been published forbidding or warning on the reuse of SUDs. Conversely, in 
Germany, the Medical Device Act does not ban the reprocessing of medical devices labelled 
for single use and advises users and institutions to use their own discretion. Therefore, 
catheters are processed for reuse in many hospitals in Germany. The regulative answer 
provided by the German legal system to reprocessing represents a possible balance between 
the need to maximize the efficiency of the health care system and the safeguard of patient 
health and safety. German legislation on matter of reprocessing comes from specific 
definitions in the MDD European directive transposition. In the German case, manufacturer’s 
indication for “single usage” is not considerable in the notion of “intended purpose”. This 
eliminates any implicit ban of reprocessing practice and avoids the assimilation of reprocessor 
to manufacturer, so considering the reprocessing activity differently from “fully refurbishing”. 
Moreover reprocessing does not entail a placing of the device in the market since after process 
it is still delivered to the first purchaser who represents the effective owner. This fact allowed 
to not re-marking the devices with a new CE label. The third party reprocessor provides the 
possibility of unique identification and the re-delivering to the sole owner. However, 
according to German regulation, the reprocessor is not exempted from carrying on complex 
procedures for process control and validation. 
The United States Food and Drug Administration increased its oversight of SUDs 
reprocessing gradually. On August 14, 2000, a new FDA policy entitled, “Enforcement 
Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals,”  was released 
to regulate third-party and hospital reprocessors of SUDs. Under the new guidelines, these 
reprocessors are considered device manufacturers. Therefore, third-party firms and 
reprocessing hospitals have to obtain pre-market approval (PMA) from the FDA for their 
products and are obligated to follow the same adverse-event reporting requirements 
(Medical Device Reporting) as OEMs.  
The reprocessors, whether third-party firms or hospitals, are also required to register their 
establishment with the FDA, provide a list of devices they reprocess, establish a medical-
device tracking system, conform to good manufacturing practice requirements, and follow 
general labelling requirements regarding the name and site of reprocessing and inclusion of 
adequate directions for use. 
The Australian Government does not endorse the reuse of SUDs and requires informed 
consent from patients if a reprocessed device is to be used.  
Reuse of SUDs was common practice in Canada before august 1996. At that time the 
government advised to discontinue the practice of reusing SUDs primarily because of 
concern about the potential risk of blood borne Creutzfeldt-Jakob disease. However, in 
Canada, there are no Federal or Provincial regulations governing the reuse of single-use 
medical devices. Currently, Health Canada does not regulate the reuse of medical devices 
by health care facilities or reprocessing of these devices by third-party reprocessors. The use 
or reuse of medical devices falls outside the governance of the Food and Drugs Act and the 
Medical Devices regulations. These acts have authority over the manufacture and sale of 
medical devices and were never intended as regulations over the use (including reuse) of 
such medical devices. 
5.2 The ethical issue 
From an ethical standpoint, two main aspects have to be considered: patients safety and 
distributive justice in allocating available resources. The focus of the concern should be 
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upon the ethical obligation of all health care professionals/ institutions to cause no harm or 
injury to their patients, but the issue is complicated by important considerations involving 
the appropriate allocation of increasingly scarce health resources. In an era of enormous 
restriction of resources in the health care system, the incentive to save money is a legitimate 
claim. From an ethical perspective, any wastefulness in unjustifiable in a health care system 
where a patient may be denied a service because a lack of resources, (CETSQ, 1994). As 
such, reuse may not be unethical so long as it is established that the quality of care is 
maintained and there is no significant loss of device effectiveness and no unreasonable 
increased risk of harm to the patient. Anyway, economic saving should not be at the 
expense of patient safety and the focus of any consideration of the practice of reuse must be 
the patient (NHMRC, 1997).  
At the same time it is included in the ethical debate the importance to spread goods and 
technologies in less privileged countries. It was reported that in different health systems the 
risk/ efficacy ratio could be substantially different and the most of the clinical work can be 
done with less technological support than that typically available in more affluent countries 
(Ruffy, 1995). On a secondary level, hospitals which reuse SUDs may be fulfilling their 
societal obligations to protect the environment through decreased landfill disposal, 
providing that the substituted cleaning and sterilization procedures are not of increased 
harm to the environment (CHA, 1996). 
5.3 Patient’s informed consent 
Patients have the right to know and physician should not be reluctant to disclose 
information about reuse and reprocessing of single use devices to the patient. Both 
individual patients and public trust requires that openness is exercised and that the practice 
of reuse is not concealed in any way. A hospital’s policy in this regard must therefore be 
public knowledge and clearly disclosed (CETSQ, 1994). However there are different 
opinions regarding the need for obtaining patient’s consent about reusing SUDs. Usual 
ethical perspectives on informed consent could be grouped in two different positions. 
The first concludes that patients should be always advised when reusing SUDs because the 
risk of this practice has not been adequately studied. Some ethicists believe, moreover, that 
the informed consent of a patient is ethically necessary, since there is an obligation on 
medical staff not to lie, deceive or otherwise interfere with a patient's free choice (Hall, 
1991). This opinion is, in some points, also reflected in the original equipment 
manufacturers (OEMs) position about SUDs reuse. Producer remarks that it is a basic 
principle of medical treatment that the patient should consciously agree to the form of 
treatment. It is OEMs’ opinion that patient should be clearly told of all relevant factors, 
including the fact that he is to be treated with a reused single-use device contrary to the 
manufacturer’s instructions, and that this may expose the patient to possible additional risks 
(EUCOMED, 2002).  
The second ethicists’ perspective concluded that the need to obtain informed consent for 
reused SUDs depends on if the physician believes there is an appreciable and significant risk 
for the patient. In this approach it is supposed that no substantial differences in safety and 
efficiency are imputable to reprocessed devices in respect to new ones. This perspective 
considers that the risk of a life-threatening or fatal complication during the clinical 
intervention is always present. As an example, in the case of electrophysiological studies, 
such a risk is in the range of 1:1000 (Horowitz, 1986). Conversely, the risk of reusing 
electrophysiological catheters appears to be so low that no reasonable estimate has been 
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identified yet. Relative to the overall risk of the procedure, the risk of reusing the devices 
might become insignificant. 
It is in the opinion of the North America Society of Pacing and Electrophysiology (Lindsay 
et al., 2001) that, if the use of reprocessed EP devices is not associated with material and 
functional risk, then there is no ethical reason why this issue must be added to the long list 
of risks known to be associated with the procedure. Patients should be informed if they ask 
about the hospital’s policy and they have the right to request that reprocessed catheter not 
be used. The decision to include this discussion when informed consent is obtained should 
be determined by the attending physician. If a patients objects to the use o a reused catheters 
it is up to the hospital to decide whether a new catheter will be provided or whether the 
patient will have to assume the risk of a delay in treatment until a new catheter became 
available in the course of routine (CETSQ, 1994). 
A study on the patient acceptance of reused angioplasty equipment showed that a sufficient 
number (68%) of patients would be willing to permit reused PTCA devices (Vaitkus & 
Burlington, 1997). The same study pointed out that the disapproval by one third of patient 
raises the possibility of adverse publicity and litigation for institution implementing a reuse 
policy. However the perception of duplicity in medical care when informed consent is 
obtained is of particular concern.  
6. Economic issues 
6.1 Cost-minimization model 
To estimate the potential saving for budgets of cardiology departments, a cost-minimization 
model was developed by Capri and colleagues (Capri et al. 2005) and applied to data 
pertaining to the Italian health system (Tessarolo et al., 2007b; Tessarolo et al., 2009). The 
model was developed in the hypothesis that reprocessing and reuse of SUDs is performed 
by guaranteeing safety and efficiency of the reconditioned device as high as the new one.  
The model was used to describe the costs associated to catheters for interventional 
cardiology at departmental level in two different scenarios: single-use policy and re-use 
policy. Device reprocessing in case of reuse policy was designed by considering a third 
party professional reprocessor. Accordingly to the model, the single-use catheter’s cost (cK ) 





= + +  (1) 
 
Where Pk is the new catheter price, S is the cost related to special waste disposal per single 
device, N is the total number of used catheters per year in the modelled cardiology 
department, and GK is the cost for a competitive triennial contracts allocation of new 
devices. Differently, in case of reprocessing and reuse of cardiac catheters, the expression 
was modified as follows: 
 
( ) ( )K R K RR KP n 1 P S G Gc i 1 i P C
n n 3N 3N
+ −= + − + + + +  (2) 
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Where cR is the cost for n-times used device, i is the reprocessing rate, PR is the reprocessing 
cost per catheter, n is the maximal number of uses sustainable by the catheter. Additional 
parameters were considered, as costs related to collection and handling of used catheter 
after each use (C), and costs for competitive triennial contracts allocation of reprocessing 
service (GR). Potential saving, related to the introduction of a reprocessing SUDs policy, 






−= ⋅  (3) 
6.2 Potential saving from SUDs reprocessing in interventional cardiology   
Accordingly to previous finding on safety and effectiveness, the maximum number of uses 
(n) to enter in the cost-minimization model was set at 6 and 3 for EP and PTCA catheters 
respectively. 
For a cardiology department with a median number of intervention (600 angioplasties and 
200 electrophysiological studies per year) the model forecasted a potential saving of about 
12% in the expenditure for PTCA catheter if reprocessing and reuse policy is adopted 
(Tessarolo et al., 2009). A markedly higher saving of about 41% and 33 % was computed for 
EP diagnostic and ablation procedures respectively. The sensitivity analysis on the three 
main variables, those are regeneration rate, number of uses, and catheter consumption per 
year, showed that significant differences in savings between EP and PTCA catheters 
reprocessing are mostly related to the annual catheter consumption that is proportional to 
cardiac department activity (Fig. 8). Major variations in savings occurred in the range 
between 1 and 200 catheters per year.  
Percent savings generally grew as a function of regeneration rate (i) and maximum number 
of uses (n), but for high number of catheter usage per year (i.e. greater than 300) there was a 
tendency to a linear relation between percent savings and regeneration rate, while a plateau 
in percent saving was reached by increasing the maximum number of uses. 
The economic analysis indicated that reuse of SUDs might be a source of savings for the 
cardiology department. However, the scaling to a specific working unit should be done 
cautiously. Since the cost saving depends on the number of devices used per year, 
regeneration might be economically unfavourable if a small number of clinical interventions 
is performed. The number of catheter used per year is therefore the most immediate 
parameter for establishing the cut off between benefits and charges in reprocessing SUDs. 
An additional critical point is the price of new device. Namely, decrease in the cost of new 
devices could sensibly modify potential saving and, in case of limited percents of benefits as 
PTCA catheters, a decrease in new device price could nullify the benefit of reprocessing 
(Capri et al., 2005). Moreover innovations in devices or reprocessing technology could affect 
the final savings by altering the maximum number of regenerations and the regeneration 
rate. Anyway, market dynamics forces to make stable the ratio between new catheter prices 
and regenerated device’s cost, usually placed in the range of 0.4-0.5 by third party 
reprocessor.  
Finally, quotes for patient’s insurance and risk management should be introduced in the 
model, and more complex cost-effective analyses and decisional processes have to be 
applied in case reprocessed device is not as safe and effective as the new one (Sloan, 2007). 
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Fig. 8. Sensitivity analysis surface plots for potential percents saving  of a reprocessing 
policy calculated according to the economic model. Left column: variation of the 
regeneration rate. The number of uses per catheter type has been set to 3, 6, and 6 for (a) 
PTCA, (b) EP diagnostic, and (c) EP ablation catheters respectively. Right column: variation 
of the number of uses. The regeneration rate per catheter type has been set to 0.48, 0.95, and 
0.95 for (a) PTCA, (b) EP diagnostic, and (c) EP ablation catheters respectively. Adapted 
from Tessarolo et al., 2009. 
7. Conclusions 
From a technical and hygienic perspective the most efficient and safe reprocessing protocol 
should contemplate a unique and continuative solution, which provide for all the treatments 
starting from collection of used devices in cardiology departments to sterilization. This 
approach to regeneration, while assuring the best hygienic performances, requires devoted 
infrastructures, trained staff and specific knowledge. These technical considerations added 
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to organizational, economic, and legal requirements connected to the need to qualify and 
certify all reprocessing procedures, suggest the introduction of this practice only in hospitals 
and health care structures with a significant workload. Anyway the more and more 
stringent criteria required by legislation and regulative policies underline the need for 
guaranteeing a certified reprocessing procedure, with the same quality issues supplied by 
the original manufacturers. These requirements may be unlikely achieved by small or 
medium hospitals, but could be affordable by relevant health care institutions or by third 
party industry reprocessors. 
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